J.P. Morgan Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $40
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Mettler-Toledo (MTD)
AtriCure Is Maintained at Buy by Canaccord Genuity
AtriCure Analyst Ratings
CCORF Maintains AtriCure(ATRC.US) With Buy Rating, Raises Target Price to $61
A Quick Look at Today's Ratings for AtriCure(ATRC.US), With a Forecast Between $36 to $60
AtriCure Is Maintained at Overweight by JP Morgan
UBS Maintains Buy on AtriCure, Raises Price Target to $40
A Quick Look at Today's Ratings for AtriCure(ATRC.US), With a Forecast Between $36 to $60
AtriCure Analyst Ratings
CCORF Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $49
Atricure's Market Strength and Innovation Justify Buy Rating
Oppenheimer Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $32
Navigating 6 Analyst Ratings For AtriCure
AtriCure Price Target Cut to $53.00/Share From $58.00 by BTIG
JP Morgan Maintains Overweight on AtriCure, Lowers Price Target to $30
A Quick Look at Today's Ratings for AtriCure(ATRC.US), With a Forecast Between $26 to $60
Needham Maintains Buy on AtriCure, Lowers Price Target to $34
AtriCure Price Target Cut to $40.00/Share From $65.00 by Piper Sandler
AtriCure Analyst Ratings